{"id":934795,"date":"2026-10-20T10:04:10","date_gmt":"2026-10-20T10:04:10","guid":{"rendered":"https:\/\/www.newsbeep.com\/au\/934795\/"},"modified":"2026-10-20T10:04:10","modified_gmt":"2026-10-20T10:04:10","slug":"ccrcc-kidney-cancer-pet-ct-imaging-approach-improves-lesion-detection-healthcare-in-europe-com","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/au\/934795\/","title":{"rendered":"ccRCC kidney cancer: PET\/CT imaging approach improves lesion detection \u2022 healthcare-in-europe.com"},"content":{"rendered":"<p><a class=\"fancybox content-img\" rel=\"fancybox nofollow noopener\" href=\"https:\/\/healthcare-in-europe.com\/media\/story_section_text\/46648\/image-01-esra-arslan-portrait_hires.jpg\" title=\"Professor Esra Arslan\" target=\"_blank\"><img decoding=\"async\" src=\"https:\/\/www.newsbeep.com\/au\/wp-content\/uploads\/2026\/10\/image-01-esra-arslan-portrait.jpg\" alt=\"Portrait photo of Professor Esra Arslan\" \/><\/a><\/p>\n<p>Professor Esra Arslan<\/p>\n<p>Photo\u00a0courtesy of Prof. Arslan<\/p>\n<p>Across 492 true lesions evaluated in the study, [68Ga]Ga-DPI-4452 PET\/CT detected 90.9%, compared with 56.7% using 18F-FDG PET\/CT. The difference was even greater in ccRCC, where [68Ga]Ga-DPI-4452 PET\/CT detected 97.9% of lesions compared with 47.1% using 18F-FDG PET\/CT. Patient-level diagnostic accuracy in ccRCC was also higher, at 98.2% compared with 77.2%.\u00a0<\/p>\n<p>\u201cCAIX gives us a highly selective biological target,\u201d explained lead author Professor Esra Arslan. \u201cIt is expressed at a very high rate in ccRCC, while expression in normal renal tissue remains minimal. This gives us the potential to distinguish tumour from surrounding healthy tissue much more clearly.\u201d\u00a0<\/p>\n<p>By contrast, 18F-FDG measures glucose metabolism, but its effectiveness in RCC can be limited by high physiological glucose uptake and intense urinary excretion in the kidneys, which can make tumours harder to distinguish from surrounding tissue. Some low-grade tumours also take up relatively little 18F-FDG, making them more difficult to detect.\u00a0<\/p>\n<p>Tumour uptake with [68Ga]Ga-DPI-4452 was approximately five times higher than with 18F-FDG, while the tumour-to-background ratio \u2013 a measure of how clearly a tumour stands out from surrounding tissue \u2013 was around ten times greater. Higher lesion detection was seen across several metastatic sites, including the lymph nodes, lungs, bones, brain and soft tissues.\u00a0<\/p>\n<p>The difference was particularly striking in brain metastases, where high physiological 18F-FDG uptake can make lesions difficult to distinguish. [68Ga]Ga-DPI-4452 PET\/CT detected all identified brain metastases, with a median maximum tumour-to-background ratio of 281.3 compared with 0.7 for 18F-FDG. [68Ga]Ga-DPI-4452 PET\/CT also detected all identified lung metastases compared with around half using 18F-FDG PET\/CT, while lymph-node detection was 95.0% versus 68.9%.\u00a0<\/p>\n<p>One exception was liver metastases. Across the overall RCC cohort, FDG performed better in the liver, reflecting lower and more variable CAIX expression in some non-clear cell RCC subtypes. Within the ccRCC subgroup, however, performance again favoured [68Ga]Ga-DPI-4452.\u00a0<\/p>\n<p>Importantly, [68Ga]Ga-DPI-4452 PET\/CT resulted in a change in clinical management or disease stage in 30.9% of patients, compared with 5.9% using 18F-FDG PET\/CT. Changes included identifying previously undetected recurrent or residual disease, detecting nodal or distant metastases that resulted in upstaging and reclassifying some patients from oligometastatic to more widespread metastatic disease. In three patients, findings considered positive on 18F-FDG PET\/CT were excluded by [68Ga]Ga-DPI-4452 PET\/CT, which the researchers reported avoided unnecessary interventions.\u00a0<\/p>\n<p>Looking ahead, the researchers, Professor Arslan and Professor Dr Halil K\u00f6mek, who contributed equally to this work, see potential roles for CAIX-targeted PET\/CT in initial staging before nephrectomy or metastasectomy, restaging when recurrence is suspected and, in the future, as part of a theranostic approach in which [68Ga]Ga-DPI-4452 PET\/CT could help identify patients suitable for treatment with [177Lu]Lu-DPI-4452.<br \/>\u201c[68Ga]Ga-DPI-4452 has the potential to become a valuable tool across several stages of RCC management,\u201d said Professor Arslan. \u201cHowever, it is premature to claim that this agent represents a \u2018new molecular imaging standard\u2019 without validation in larger, multicentre studies stratified by subtype.\u201d\u00a0<\/p>\n<p>Further research will be needed to validate the findings in larger patient populations and across different RCC subtypes, where CAIX expression can be lower and more variable. Longer-term prospective studies will also be important to determine whether the observed changes in disease staging and clinical management ultimately translate into improved patient outcomes.\u00a0<\/p>\n<p>References:\u00a0<\/p>\n<p>Arslan E, K\u00f6mek H, Can C, Akg\u00fcn E, \u00c7ermik TF, K\u0131l\u0131\u00e7 R, et al. Beyond FDG: CAIX-targeted PET achieves near-complete tumor detection in renal cell carcinoma. Presented at: 39th Annual Congress of the European Association of Nuclear Medicine (EANM\u201926); 20 October 2026; Vienna, Austria. Presentation OP-624.\u00a0Cleveland Clinic. Renal cell carcinoma. Available at: <a href=\"https:\/\/my.clevelandclinic.org\/health\/diseases\/24906-renal-cell-carcinoma\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">https:\/\/my.clevelandclinic.org\/health\/diseases\/24906-renal-cell-carcinoma<\/a>. Accessed 21 September 2026.\u00a0K\u00f6mek H, Arslan E, Can C, Akg\u00fcn E, K\u0131l\u0131\u00e7 R, Y\u00fcceta\u015f U, et al. From metabolism to molecular phenotype: carbonic anhydrase IX-targeted [68Ga]Ga-DPI-4452 PET\/CT in renal cell carcinoma: a prospective multicenter comparison with [18F]FDG PET\/CT. J Nucl Med. 2026 Sep 17:jnumed.126.273011. doi:<a href=\"https:\/\/doi.org\/10.2967\/jnumed.126.273011\" title=\"\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">10.2967\/jnumed.126.273011<\/a>. [Epub ahead of print]\u00a0Arslan E, K\u00f6mek H, Can C, Akg\u00fcn E, T\u00fcrk O, Y\u00fcceta\u015f U, et al. One tracer, whole syndrome: CAIX-targeted PET unmasks the multisystem tumor landscape of von Hippel-Lindau disease. Clin Nucl Med. 2026 Sep 24. <a href=\"https:\/\/doi.org\/doi:10.1097\/RLU.0000000000006674\" title=\"\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">doi:10.1097\/RLU.0000000000006674<\/a>. [Epub ahead of print]\u00a0Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W, et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42(2):328\u2013354. <a href=\"https:\/\/doi.org\/10.1007\/s00259-014-2961-x\" title=\"\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">doi: 10.1007\/s00259-014-2961-x.<\/a>\u00a0Franquet E, Park H. Molecular imaging in oncology: Common PET\/CT radiopharmaceuticals and applications. Eur J Radiol Open. 2022;9:100455. <a href=\"https:\/\/doi.org\/10.1016\/j.ejro.2022.100455\" title=\"\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">doi:10.1016\/j.ejro.2022.100455.<\/a>\u00a0Bex A, Abu Ghanem Y, Albiges L, Bonn S, Campi R, Capitanio U, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2025 Update. Eur Urol. 2025;87(6):683\u2013696. <a href=\"https:\/\/doi.org\/10.1016\/j.eururo.2025.02.020\" title=\"\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">doi: 10.1016\/j.eururo.2025.02.020.<\/a><\/p>\n<p>Source: European Association of Nuclear Medicine\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"Professor Esra Arslan Photo\u00a0courtesy of Prof. Arslan Across 492 true lesions evaluated in the study, [68Ga]Ga-DPI-4452 PET\/CT detected&hellip;\n","protected":false},"author":2,"featured_media":934796,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[64,63,137,501508,501509,501507],"class_list":["post-934795","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-au","tag-australia","tag-health","tag-presented-at-eanm_nucmed-039s-eanm26-congress-bristanbuleah","tag-presented-at-the-officialeanm-039s-eanm26-congress-in-vienna-brpresented-at-eanm-org-039s-eanm26-congress-in-vienna","tag-x-istanbuleah-and-diyarbakir_eah"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/934795","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/comments?post=934795"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/934795\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media\/934796"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media?parent=934795"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/categories?post=934795"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/tags?post=934795"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}